新浪登录
腾讯登录AIDS：艾滋病感染者14.6%感染乙肝
| 导读 | <div id="region-column1and2-layout2">
<div> 北京协和医院日前消息，医院感染内科李太生教授等在国家“十一五”课题支持下，经过4年研究，在国际上率先报告了中国艾滋病（HIV）感染人群中14.6%合并乙肝感染（HBV），但高共感率并未影响到目前国产一线抗艾药物的疗效和药品造成的肝毒性。</div>
&... |
<div id="region-column1and2-layout2">
<div> 北京协和医院日前消息，医院感染内科李太生教授等在国家“十一五”课题支持下，经过4年研究，在国际上率先报告了中国艾滋病（HIV）感染人群中14.6%合并乙肝感染（HBV），但高共感率并未影响到目前国产一线抗艾药物的疗效和药品造成的肝毒性。</div>
</div>
<div id="region-column1and2-layout2">
这一重要发现5月17日在线发表于全球艾滋病领域最著名的杂志《艾滋病》（<em>AIDS</em>）上。
<!--more-->
据介绍，经过长期规范的“鸡尾酒”治疗后，艾滋病患者体内病毒得到有效控制，由机会性感染引发的艾滋病患者死亡率逐年下降。但与此同时，合并肝脏、肾脏、心血管及神经系统的疾病以及糖尿病等代谢性疾病，正成为困扰艾滋病患者健康状况的主因。其中肝脏疾病是艾滋病患者经有效“鸡尾酒”治疗后死亡的第一原因。
早在2008年，李太生便带领课题组从全国12个医疗中心募集了550名艾滋病感染者纳入该项研究，结果发现，艾滋病毒感染人群中14.6%合并感染慢性乙肝，合并感染者免疫水平相对较低。李太生分析，这种结果可能为二者感染途径相同、艾滋病病毒感染后免疫力的下降使乙肝感染率提高所致。
他指出，值得欣慰的是，研究同时发现，目前国产一线抗艾药物对艾滋病感染的治疗效果并不受是否感染乙肝病毒的影响，这些药物产生肝毒性的几率也较小。
<div id="ztload">
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201206/2012060610304118.jpg" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/doi:10.1097/QAD.0b013e328355ced2" target="_blank">doi:10.1097/QAD.0b013e328355ced2</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort</strong><br/>
Wang, Huanling; Li, Yijia; Zhang, Chengda; Han, Yang; Zhang, Xiaoying; Zhu, Ting; Li, Taisheng
Objective: To evaluate the influence of hepatitis B virus (HBV) co-infection on immunological, virological and clinical responses to lamivudine-based combined antiretroviral therapy (cART) in Chinese patients. Design and methods: This prospective, multicenter cohort study recruited 529 antiretroviral-naive participants (aged 18-65 years, both genders) between 2008 and 2010. They were grouped by HBV serostatus. Virological and immunological responses were monitored at baseline and week 4, 8, 12, 24, 36 and 48. cART for all patients was nevirapine, lamivudine with either zidovudine or stavudine. Results: (1)HIV/HBV co-infection rate in our cohort was 14.6%. (2)Among 508 patients with complete baseline information, median CD4 level was significantly lower in chronic HBV-infected (CHB) group and isolated-core group. In CHB group, HBeAg positivity rather than HBV DNA level was associated with lower CD4 count. (3)In isolated-core group, occult infection rate was 9.5%. (4)At week 48, rate of HIV suppression below 40 copies/mL was 74.2%. Median increase in CD4 at week 48 was 127cells/[mu]L. Of note, HBV serostatus did not influence virological and immunological response to cART at each follow-up time point. Although HBV serostatus was associated with different ALT level during follow-up, hepatitis and hyperbilirubinemia rates were not significantly different. (5)3TC-based regimen was efficacious against HBV replication, with median decrease of HBV DNA 2.87 log copies/mL. However, HBeAg positivity was associated with poorer HBV DNA suppression. Conclusion: In our cohort, chronic HBV infection and isolated HBcAb positivity were related to faster HIV progression. Despite of this, virological and immunological responses were not affected by HBV serostatus. (C) 2012 Lippincott Williams & Wilkins, Inc.
<br/>来源：新京报
</div>
</div>
</div>
</div>
<div> 北京协和医院日前消息，医院感染内科李太生教授等在国家“十一五”课题支持下，经过4年研究，在国际上率先报告了中国艾滋病（HIV）感染人群中14.6%合并乙肝感染（HBV），但高共感率并未影响到目前国产一线抗艾药物的疗效和药品造成的肝毒性。</div>
</div>
<div id="region-column1and2-layout2">
这一重要发现5月17日在线发表于全球艾滋病领域最著名的杂志《艾滋病》（<em>AIDS</em>）上。
<!--more-->
据介绍，经过长期规范的“鸡尾酒”治疗后，艾滋病患者体内病毒得到有效控制，由机会性感染引发的艾滋病患者死亡率逐年下降。但与此同时，合并肝脏、肾脏、心血管及神经系统的疾病以及糖尿病等代谢性疾病，正成为困扰艾滋病患者健康状况的主因。其中肝脏疾病是艾滋病患者经有效“鸡尾酒”治疗后死亡的第一原因。
早在2008年，李太生便带领课题组从全国12个医疗中心募集了550名艾滋病感染者纳入该项研究，结果发现，艾滋病毒感染人群中14.6%合并感染慢性乙肝，合并感染者免疫水平相对较低。李太生分析，这种结果可能为二者感染途径相同、艾滋病病毒感染后免疫力的下降使乙肝感染率提高所致。
他指出，值得欣慰的是，研究同时发现，目前国产一线抗艾药物对艾滋病感染的治疗效果并不受是否感染乙肝病毒的影响，这些药物产生肝毒性的几率也较小。
<div id="ztload">
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201206/2012060610304118.jpg" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/doi:10.1097/QAD.0b013e328355ced2" target="_blank">doi:10.1097/QAD.0b013e328355ced2</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort</strong><br/>
Wang, Huanling; Li, Yijia; Zhang, Chengda; Han, Yang; Zhang, Xiaoying; Zhu, Ting; Li, Taisheng
Objective: To evaluate the influence of hepatitis B virus (HBV) co-infection on immunological, virological and clinical responses to lamivudine-based combined antiretroviral therapy (cART) in Chinese patients. Design and methods: This prospective, multicenter cohort study recruited 529 antiretroviral-naive participants (aged 18-65 years, both genders) between 2008 and 2010. They were grouped by HBV serostatus. Virological and immunological responses were monitored at baseline and week 4, 8, 12, 24, 36 and 48. cART for all patients was nevirapine, lamivudine with either zidovudine or stavudine. Results: (1)HIV/HBV co-infection rate in our cohort was 14.6%. (2)Among 508 patients with complete baseline information, median CD4 level was significantly lower in chronic HBV-infected (CHB) group and isolated-core group. In CHB group, HBeAg positivity rather than HBV DNA level was associated with lower CD4 count. (3)In isolated-core group, occult infection rate was 9.5%. (4)At week 48, rate of HIV suppression below 40 copies/mL was 74.2%. Median increase in CD4 at week 48 was 127cells/[mu]L. Of note, HBV serostatus did not influence virological and immunological response to cART at each follow-up time point. Although HBV serostatus was associated with different ALT level during follow-up, hepatitis and hyperbilirubinemia rates were not significantly different. (5)3TC-based regimen was efficacious against HBV replication, with median decrease of HBV DNA 2.87 log copies/mL. However, HBeAg positivity was associated with poorer HBV DNA suppression. Conclusion: In our cohort, chronic HBV infection and isolated HBcAb positivity were related to faster HIV progression. Despite of this, virological and immunological responses were not affected by HBV serostatus. (C) 2012 Lippincott Williams & Wilkins, Inc.
<br/>来源：新京报
</div>
</div>
</div>
</div>
还没有人评论，赶快抢个沙发